EnterNext welcomes Kiadis Pharma on Euronext Amsterdam and Euronext Brussels


Kiadis Pharma raises € 32.7 million in successful IPO

Amsterdam, Brussels – 2 July 2015– EnterNext, the Euronext subsidiary designed to promote and grow the market for SMEs, today welcomed Kiadis Pharma on the Amsterdam and Brussels market of Euronext (ticker code: KDS).

Kiadis Pharma is a clinical stage biopharmaceutical company focused on research, development and future commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The company is committed to developing innovative and potentially life‑saving therapies for patients with late-stage blood cancers and patients with inherited blood disorders, who are in need of a transplant, an area of significant unmet medical need.

The total offering of Kiadis Pharma was valued at € 32.7 million. After opening, the market price was € 12.50 per share. Based on the opening price, the total market capitalization of the company was approximately € 166.4 million.

Manfred Rüdiger, CEO Kiadis Pharma, said: “We are delighted to have joined Euronext today. Kiadis Pharma's IPO received significant interest from local, European and US investors and now we intend to advance our pipeline of products that will potentially save the lives of thousands of blood cancer and inherited blood disorder patients.”

“We would like to congratulate Kiadis Pharma on its successful IPO”, said Maurice van Tilburg, CEO of Euronext Amsterdam. “It is great to see another biopharmaceutical company list on our markets. This transaction confirms the stockmarket’s appeal for biotech companies, allowing them to raise the capital they need to step up the pace of development.“

Vincent van Dessel, CEO Euronext Brussels, added: “We are delighted to welcome Kiadis Pharma today to Euronext, Europe’s most active market for life sciences. Through EnterNext we are fully committed to support the company in its objective to become a leading biopharmaceutical company focused on developing and commercialising therapeutic products in cell-based immunotherapy.”

To celebrate the listing, CEO of Kiadis Pharma Manfred Rüdigersounded the gong in Amsterdam to open trading on Euronext’s markets.


Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With more than 1,900 listed issuers and around €6.5 trillion in market capitalisation as of end June 2023, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2023, Euronext N.V. - All rights reserved.